Suppr超能文献

组胺在小鼠和大鼠肿瘤生长中的作用:单氟甲基组氨酸的抗肿瘤特性,一种组氨酸脱羧酶的酶激活不可逆抑制剂。

Involvement of histamine in growth of mouse and rat tumors: antitumoral properties of monofluoromethylhistidine, an enzyme-activated irreversible inhibitor of histidine decarboxylase.

作者信息

Bartholeyns J, Bouclier M

出版信息

Cancer Res. 1984 Feb;44(2):639-45.

PMID:6692368
Abstract

The present study suggests that newly synthesized histamine is involved in the development of some animal tumors (e.g., Lewis lung carcinoma in mice and Morris hepatoma in rats). A marked induction of histidine decarboxylase (HDC) and an increase in the histamine concentration were observed in the tumors approximately 1 week after inoculation, and there were parallel increases in ornithine decarboxylase activity and the concentrations of polyamines. The H2 receptor antagonist, cimetidine, significantly reduced tumor growth in the animal models while the H1 receptor antagonist, dexchlorpheniramine, had no effect, suggesting that histamine could act via H2 receptor sites. Extensive depletion of tumor histamine induced by local injection of Compound 48/80 did not result in a significant cytostatic effect. Monofluoromethylhistidine (MFMH), an enzyme-activated irreversible inhibitor of HDC, retarded the growth of hepatoma tissue culture cells grown in culture, and when infused s.c. at 60 mg/kg/day it greatly inhibited the development of tumors induced i.m. by hepatoma tissue culture cells in Buffalo rats. MFMH also had pronounced antitumoral effects on EMT6 sarcomas and Lewis lung carcinomas in mice, which were associated with inhibition of HDC and depletion of the histamine content of the tumors. These cytostatic effects were clearly enhanced when MFMH was combined in therapy with the specific ornithine decarboxylase inhibitor, DL-alpha-difluoromethylornithine. The antitumoral effects of the combination were associated with marked decreases in the tumor histamine and putrescine contents. It is proposed that nascent histamine, like newly synthesized putrescine and spermidine, plays a role in the rapid proliferation of animal tumors. Inhibition of HDC by essentially nontoxic drugs such as MFMH could represent a novel approach to the control of neoplastic growth.

摘要

本研究表明,新合成的组胺参与了某些动物肿瘤的发生发展(例如小鼠的Lewis肺癌和大鼠的Morris肝癌)。接种后约1周,在肿瘤中观察到组胺酸脱羧酶(HDC)明显诱导以及组胺浓度增加,同时鸟氨酸脱羧酶活性和多胺浓度也平行增加。H2受体拮抗剂西咪替丁在动物模型中显著降低了肿瘤生长,而H1受体拮抗剂右氯苯那敏则无此作用,这表明组胺可能通过H2受体位点发挥作用。局部注射化合物48/80诱导肿瘤组胺大量耗竭并未产生显著的细胞生长抑制作用。单氟甲基组胺(MFMH)是一种酶激活的不可逆HDC抑制剂,可抑制培养的肝癌组织培养细胞的生长,当以60mg/kg/天的剂量皮下注射时,它能极大地抑制布法罗大鼠肌肉注射肝癌组织培养细胞诱导的肿瘤发展。MFMH对小鼠的EMT6肉瘤和Lewis肺癌也有明显的抗肿瘤作用,这与HDC的抑制和肿瘤组胺含量的减少有关。当MFMH与特异性鸟氨酸脱羧酶抑制剂DL-α-二氟甲基鸟氨酸联合治疗时,这些细胞生长抑制作用明显增强。联合用药的抗肿瘤作用与肿瘤组胺和腐胺含量的显著降低有关。有人提出,新生组胺与新合成的腐胺和亚精胺一样,在动物肿瘤的快速增殖中起作用。用MFMH等基本无毒的药物抑制HDC可能代表一种控制肿瘤生长的新方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验